Ultimately, studies to characterize the HDAC-isoform selectivity and downstream molecular targets of PTBA will further our understanding of how this class of compound mitigates renal injury and advance efforts to develop a new drug therapy for AKI. Here, HDAC9 is linked to acute kidney injury.